Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STUDIO POLE-END REAL LIFE: Carcinoma Dell'Endometrio Stadi Precoci I-II e Avanzati III e IV Valutazione di POLE Come Fattore Prognostico

NCT06409039 is registered in ClinicalTrials.gov with Azienda Ulss 2 Marca Trevigiana as lead sponsor.

NCT NCT06409039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06409039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STUDIO POLE-END REAL LIFE: Carcinoma Dell'Endometrio Stadi Precoci I-II e Avanzati III e IV Valutazione di POLE Come Fattore Prognostico
Lead sponsor
Azienda Ulss 2 Marca Trevigiana
Phase
Observational
Overall status
Unknown status
Start date
September 4, 2023
Completion date
December 31, 2024
Enrollment
80 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial neoplasms